Top Tech Companies (2,065)
Don't see your company?
Create a company profile
Wake Research is an integrated network of premier investigational sites working closely with and meeting the needs of the global biopharmaceutical, biotechnology, medical device, pharmaceutical industry, and clinical research organizations. Wake Research has its proprietary patient database of more than 2 million potential clinical trial participants—men and women, children and adults, across all ethnicities—for all kinds of adaptive and other types of trial designs. Conducting studies since 1984, we have a combined subject database of more than 2 million, and we’re still growing. As of today, our board-certified physicians have completed more than 7,000 successful clinical trials. Clinical trials at our site are always completed on time and with accuracy; we consistently exceed sponsor expectations for integrity, subject enrollment, human protection, and expeditious delivery of accurate evaluable data. Our approach is uncompromising – each study conducted at our site is carefully planned and executed according to regulations with superior quality.
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Learn more: www.AjiBio-Pharma.com
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.
Chemistry is the key to drug discovery, but chemical data is stuck in the twentieth century. We’re generating precise chemical datasets purpose-built to propel drug discovery into the information age — and we’re doing it on a larger scale and faster than has ever before been possible. Terray Therapeutics is a biotechnology company led by pioneers and long-time leaders in artificial intelligence, synthetic (medicinal) chemistry, biology and preclinical development, automation, and nanotechnology. Chemical datasets generated using our novel ultra-dense microarray technology work seamlessly with our integrated machine learning and computational platform to systematically map biochemical interactions between small molecules and causes of disease. Iterative cycles of virtual molecular design and experimentation power AI and machine learning models, which in turn guide the next cycle of design. With a chemistry engine that measures billions of interactions daily and becomes increasingly precise with every cycle, we can answer an unprecedented array of questions — deriving insights that enable us to predictably create drugs for patients in need.
PERSOWN’s mission is to make accurate, low-cost point-of-care diagnostic testing and secure patient data available instantly to everyone across the globe, including those in resource-limited or logistically remote areas, in order to improve and save lives. Our vision is a world in which no one suffers or dies from communicable disease, everyone receives swift, effective care when unavoidable illness arises, and good health supported by good technology allows humankind to live each day to the fullest.
Advanced BioScience Laboratories, Inc (ABL) is a leading contract research and manufacturing organization, that partners with our clients to support their vaccine and therapeutic development programs. We offer a unique combination of preclinical and clinical services designed to first address the scientific challenges often encountered during proof-of-concept, and then streamline process development and cGMP production of clinical supply. ABL can assist with all aspects of production development including, but not limited to: Basic and translational research Vaccine and therapeutic product design Animal models for preclinical evaluation including immunomonitoring , efficacy and potency Cell line and process development cGMP manufacture of cell banks and virus banks cGMP manufacture of clinical supply for protein therapeutics, vaccines and live viral vectors Ask about our 9,000 sq ft clinical GCLP immunomonitoring space and our vaccine and therapeutic testing services. With a 50+ year history as a service provider to the life sciences industry, ABL brings a broad technical knowledge base, highly experienced work force, and seasoned project management to every program. Our goal is to become a seamless extension of our clients’ product development group – helping them advance today’s ideas into tomorrow’s medicines. Our history, capabilities and expertise allow ABL to provide solution based services to our clients.
StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond. We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBio’s AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.
Diazyme uses its proprietary enzyme technologies to develop diagnostic reagents which can be used on most automated chemistry analyzers in user-friendly formats. Diazyme’s products include test kits for diagnosis of cardiovascular disease, liver disease, cancer markers, renal disease, and electrolytes. Diazyme Laboratories is a life science affiliate of General Atomics located in Poway, California and is a cGMP and ISO 13485 certified medical device manufacturer.
WuXi Advanced Therapies - Accelerating Progress and Time to Market • Integrated Manufacturing and Testing Service Platform • Solutions From Gene of Interest to Global Commercial Launch The advanced therapies business unit of WuXi AppTec is a leading cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. Our Story By leveraging platforms and integrated testing, the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Testing, Development and Manufacturing Organization (CTDMO), pioneering the expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. Well positioned for growth, our investments in personnel and manufacturing continue to expand clinical and commercial capacities. Since 2004, WuXi AppTec has supported Advanced Therapy programs with an extensive infrastructure of state-of-the-art, GMP-compliant facilities, providing centers of excellence for manufacturing and testing.
Emerald Heath Pharmaceuticals is a biotech company developing novel therapies for neurodegenerative and autoimmune diseases. Including multiple sclerosis, systemic sclerosis (a form of scleroderma), Parkinson's disease and Huntington's disease. References/Sources: - National Multiple Sclerosis Society - Parkinson’s Foundation - Huntington’s Disease Society of America - Scleroderma Foundation - Global Multiple Sclerosis Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 To 2025 Research and Markets Report - Scleroderma Diagnostics and Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024 Transparency Market Research Report - Parkinson's Disease Therapeutics Market Global Industry Analysis Size, Share, Growth ,Trends, and Forecasts, 2017 To 2025 Transparency Market Research Report - Opportunity Analyzer: Huntington's Disease Opportunity Analysis and Forecast to 2024 Research and Markets Report
Elsie’s technology relies on a three dimensional platform that allows for the synthesis, deconvolution, and delivery of homogeneous oligonucleotide therapeutics. Our hope to leverage an out of the box way of thinking as well as a multidisciplinary approach to bring safer and more efficacious therapeutics to the market to treat the most intractable human diseases.
At Rare Disease Research, we aim to optimize the process of conducting clinical trials in rare disease conditions. To improve access to investigational therapies, increase opportunities for trial participation, patient recruitment and retention, we have an experienced team with a multidisciplinary approach to orchestrate clinical research trials in rare disease conditions. We closely collaborate with sponsors, CRO, and patient advocacy groups to improve awareness and recruitment for cutting edge clinical trials. Because rare diseases are not often considered a public health matter, we tirelessly advocate for newborn screenings. We want to improve health outcome for infants with rare genetics conditions who otherwise would have to endure diagnosis odyssey and delayed treatment. Our newborn screening project for Spinal Muscular Atrophy will begin in 2018.
Immunologix Laboratories is a unique scientific partner, offering GLP and GCP compliant laboratory capabilities focused on ligand binding-based bioanalysis coupled with expert scientific consultation from our Translational Sciences team. Our laboratory specializes in Immunogenicity, Neutralizing Antibody (cell-based and ligand binding based), PK, and Biomarker assays in support of preclinical and clinical studies. Translational Sciences provides dedicated scientific resources to advise, develop and implement scientific strategies and practical solutions for innovator development programs. Our fully customizable approach includes delivering stage-appropriate biomarker & bioanalytical strategies, assay development and validation, study data interpretation, and support for regulatory interactions and filings. Our exceptional scientific experts work together as an integrated team ensuring that our client’s projects receive full benefit of the breadth and depth of experience gained over many decades within both contract laboratory and drug development organizations. The integration of Translational Sciences with the laboratory is unique within our industry and this confluence of expertise enables our team to deliver valuable scientific insights that accelerate decision making and the course of drug development. Please contact us at [email protected]
Bioresource Technology LLC is a biotechnology company based out of 1800 N Commerce Parkway Suite 1 Weston Florida 33326
Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
Roche is dedicated to advancing personalized healthcare by creating diagnostics and treatments tailored to individual genetic and disease profiles. As part of this mission, Roche Sequencing Solutions is unifying next-generation sequencing with the goal of making it routine: Sample in, result out. Our growing suite of products spans the genomics workflow, from sample acquisition and preparation through data analysis and final result, helping you answer important questions in genetics, cancer and beyond
Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases. We are the only company advancing programs with both AAV and lentivirus vectors.
About Phamatech CORPORATE BEGINNINGS Phamatech was founded in 1991 by a small group of dedicated scientists and business executives. Combining clinical experience, technical expertise and sound business strategies, we have grown steadily over the years to become a major provider of rapid medical diagnostic devices for home healthcare and clinical settings worldwide. Relying on sophisticated, state-of-the-art technologies, Phamatech has successfully developed easy-to-use test devices that provide valuable, reliable, medical information at truly affordable prices. Phamatech is committed to manufacturing products and providing services that enhance our customer's medical care, health awareness and quality of life by aiding in the early diagnosis of medical conditions in a cost-effective manner.
TAMM Net professionals provide biomedical companies with expertise in: •Obtaining reimbursement, •Researching government funding resources, •Providing solutions to regulatory issues and applications, and •Supplying distribution to closed systems. Everyone on the TAMM Net team has over 20 years of experience in their fields with documented success.
CoreRx, Inc. is an industry leading Contract Development and Manufacturing Organization (CDMO), providing innovative drug formulation development, GMP manufacturing and packaging solutions to global pharmaceutical and bio-pharmaceutical partners. From its state-of-the-art, multi-site campus in Clearwater, Florida and its early product development center of excellence in San Rafael, California, CoreRx delivers value-added solutions to its partners, from clinic to commercial scale and across a range of dosage forms.
